Animal Health Innovation Europe | Kisaco Research
Investment, Innovation and M&A
London, UK
20-21 February, 2018
Download Agenda
The Audience
Register

Why Attend

Animal Health Investment Europe is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space.

Animal Health Innovation, Innovative Solutions in...

350+
Attendees
1300+
1-to-1 Meetings
100+
Start-ups
12
Emerging Companies Presenting
Double
the number of investors from 2017

The Agenda

Animal Health Investment Europe, 2018 agenda

New areas of focus for 2018 include nutritional health, veterinary practice, aquaculture, diagnostics and genetics, with renowned speakers:

  • GENETICS: Jonathan Lightner, Chief Scientific Officer at Genus plc
  • FUTURE OF VETERINARY: Simon Innes, Chief Executive, CVS
  • AQUACULTURE: Alf-Helge Aarskog, CEO, Marine Harvest
  • DIAGNOSTICS: Kevin S. Wilson, CEO, Heska
  • NUTRITIONAL HEALTH: Viggo Halseth, CIO, Nutreco

Download the agenda to find out more...

Animal Health Investment Europe, 2018 Agenda

Resources

Download Resource

Feedback from 2017

Animal Health Investment Forum - London, February 2017

Advisory Board

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Jishu Shi

Director, U.S.-China Center for Animal Health
Kansas State University

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Dirk Ehle

Head of Bayer Animal Health
Bayer

Linda Rhodes

VMD, PhD

George Gunn

Founder and CEO
Stonehaven Consulting AG

Aaron Schacht

Vice President - Global Research and Development
Elanco

Jean Deleforge

Chief Scientific Officer
Vetoquinol

Alan Mackay

Executive Partner and Founder
GHO Capital

From London 2017

Selection Committee

Charles Hoare

Head of Global Healthcare
Stifel

Paul Dick

President
Paul Dick & Associates Ltd

Julia Stephanus

Founder and President
Avviare

Maarten Goossens

Principal
Anterra Capital

Matthias Hofer

Partner
Stonehaven Consulting Group

Michael Hemprich

Head of Business Development
IDT-Biologika

Ronan Molloy

President
Innovation Stockyard

Simon Mason

Business Development Manager, Animal Health Division
Benchmark Animal Health

at London 2017

attended last year

Dragon's Den Panel

Marie-Paul Lachaud

Head of Program Management, Europe
Aratana Therapeutics, Inc

Samer Al-Murrani

Senior Advisor
Wombat Capital

Simon Doherty

Junior Vice President
British Veterinary Association

Irina Havias

Partner
GHO Capital

Venue

200 Aldersgate, St. Pauls, London EC1A 4HD

200 Aldersgate, venue for Animal Health Innovation Europe, London

ACCOMMODATION

Grange St. Paul’s Hotel

10 Godliman Street, London, EC4V 5AJ    (0.6 miles from 200 Aldersgate)
To book a room please email: [email protected]
Rate per night: £286.80 includes vat & Continental breakfast.
Quote Group ID 190218B when booking
Please book by 30 January 2018

 
Crowne Plaza London, The City

19 New Bridge Street, London EC4V 6DB    (0.8 miles from 200 Aldersgate)
To book a room please email: [email protected]
Telephone reservations  + 44 (0) 207 438 8040
To book online click here and use code GA1 KISACO
Rate per night: £259.00 inc. VAT & English breakfast
Always quote ‘allocation code KG5’ when booking
Please book by 7 January 2018

 
Thistle City Barbican Hotel

Monday 19th February: £155 per night inc VAT and English breakfast.
Tuesday 20th February: £170 per night inc VAT and English breakfast.
To book a room please call +44 (0) 800 330 8002 (option 2 for Groups) or email: [email protected]
Always quote 'GA1K190218' when booking
Please book by 22 Jan 2018

Conference Packages

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: discounts cannot be combined.

Saturday, December 16, 2017 to Saturday, February 24, 2018
Delegate Pass
£1,699 + VAT
Standard Pricing
Pharmaceutical Manufacturers
Digital & Tech Companies
Large Biotech Companies
Saturday, December 16, 2017 to Saturday, February 24, 2018
Service Provider Pass
£2,499 + VAT
Standard Pricing
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Distribution Companies
Saturday, November 4, 2017 to Saturday, December 16, 2017
Emerging Pass
Contact [email protected] for Discounted emerging pass rates
Early Bird prices available until 15th Dec
Pre-revenue companies
Academics
AH Biotech Companies up to £10 Million in annual revenue
Charities
Please note: Those offering consultancy or market intelligence services do not qualify for this rate
Saturday, December 16, 2017 to Saturday, February 24, 2018
Emerging Pass
Contact [email protected] for Discounted emerging pass rates
Pre-revenue companies
Academics
AH Companies up to £10 Million in annual revenue
Charities
Preparing registration...

Book a Team to Save More!

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Animal Health Investment Europe:

  • Please note that a £49 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • * Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate. *PLEASE NOTE – no additional discounts are available on ‘Emerging Company’ pricing. Partner discounts are ONLY available on ‘Industry’ pricing.

The Speakers

 

Aaron Schacht

Vice President - Global Research and Development
Elanco

Aaron Schacht

Vice President - Global Research and Development
Elanco
 

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014.

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014.

 

Alasdair Cook

Head of Department of Veterinary Epidemiology and Public Health

Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change.

Alasdair Cook

Head of Department of Veterinary Epidemiology and Public Health

Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change.

 

Alf-Helge Aarskog

Chief Executive Officer
Marine Harvest

Mr. Aarskog has served as CEO of Marine Harvest since 2010. Prior to this position, he was the CEO (2009 to 2010) and Exective Vice President (2007 to 2009) at Lerøy Seafood Group ASA. His previous positions include Managing Director (2004 to 2007) of Lerøy Midnor AS, a subsidiary of Lerøy Seafood Group ASA, and Head of Production (2002 to 2004) at Fjord Seafood ASA, a company that was later merged with ours. He holds a degree in Fish Nutrition from the University of Agriculture in Norway.

Alf-Helge Aarskog

Chief Executive Officer
Marine Harvest

Mr. Aarskog has served as CEO of Marine Harvest since 2010. Prior to this position, he was the CEO (2009 to 2010) and Exective Vice President (2007 to 2009) at Lerøy Seafood Group ASA. His previous positions include Managing Director (2004 to 2007) of Lerøy Midnor AS, a subsidiary of Lerøy Seafood Group ASA, and Head of Production (2002 to 2004) at Fjord Seafood ASA, a company that was later merged with ours. He holds a degree in Fish Nutrition from the University of Agriculture in Norway.

 

Carel du Marchie Sarvaas

Executive Director
IFAH

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

Carel du Marchie Sarvaas

Executive Director
IFAH

Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.

He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.

 

Carl Damiani

Principal
Simini Technologies

Former President and Chief Operating Officer of Transition Therapeutics, a NASDAQ listed human-focused biotechnology company acquired by OPKO Health in September 2016.  Transition developed a Phase 2/3 Alzheimer’s disease program, a Phase 2 diabetes program and held multiple partnerships with large pharma companies.  Mr. Damiani founded Simini Technologies in 2017 to develop human drug candidates as veterinary therapeutics with an initial focus on dermatology and pain management.

Carl Damiani

Principal
Simini Technologies

Former President and Chief Operating Officer of Transition Therapeutics, a NASDAQ listed human-focused biotechnology company acquired by OPKO Health in September 2016.  Transition developed a Phase 2/3 Alzheimer’s disease program, a Phase 2 diabetes program and held multiple partnerships with large pharma companies.  Mr. Damiani founded Simini Technologies in 2017 to develop human drug candidates as veterinary therapeutics with an initial focus on dermatology and pain management.

 

Clare Allen

Department of Veterinary Medicine
University of Cambridge

Dr. Allen graduated from the University of Cambridge’s Veterinary School in 1996, and completed an equine ambulatory internship at Millbrook Equine Practice in New York state. After completing her internship, and working for several different equine practices, she started teaching in an Equine Studies Program at Cazenovia College, in New York, and founded her own equine practice in the area, called White Horse Veterinary Services. Between 2005-2006 she taught at Cornell University’s College of Veterinary Medicine, and became interested in veterinary education and curriculum development.

Clare Allen

Department of Veterinary Medicine
University of Cambridge

Dr. Allen graduated from the University of Cambridge’s Veterinary School in 1996, and completed an equine ambulatory internship at Millbrook Equine Practice in New York state. After completing her internship, and working for several different equine practices, she started teaching in an Equine Studies Program at Cazenovia College, in New York, and founded her own equine practice in the area, called White Horse Veterinary Services. Between 2005-2006 she taught at Cornell University’s College of Veterinary Medicine, and became interested in veterinary education and curriculum development.

 

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

Clinton Lewis

Clinton Lewis Executive Vice President, President, International Operations
ZOETIS

Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.

 

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

Dirk Ehle

Head of Bayer Animal Health
Bayer

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

 

Erwin Blomsma

CEO
ViroVet

Erwin Blomsma holds a Master’s degree in Bioscience Engineering and a Ph.D.

Erwin Blomsma

CEO
ViroVet

Erwin Blomsma holds a Master’s degree in Bioscience Engineering and a Ph.D.

 

George Gunn

Founder and CEO
Stonehaven Consulting AG

George Gunn

Founder and CEO
Stonehaven Consulting AG
 

Gudrun Ravetz

President
British Veterinary Association

Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.

Gudrun Ravetz

President
British Veterinary Association

Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.

 

Henrik Jørck Nielsen

Vice President, Plant Health & Animal Health Innovation
Chr. Hansen

Henrik Jørck Nielsen

Vice President, Plant Health & Animal Health Innovation
Chr. Hansen
 

Irina Havias

Partner
GHO Capital

Irina is a healthcare specialist with a background in medicine and management consulting. She previously spent seven years with Bain & Company, where she was a leader in the European healthcare practice, and brings a wealth of experience across Europe, the US and emerging markets to the firm.

Irina Havias

Partner
GHO Capital

Irina is a healthcare specialist with a background in medicine and management consulting. She previously spent seven years with Bain & Company, where she was a leader in the European healthcare practice, and brings a wealth of experience across Europe, the US and emerging markets to the firm.

 

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago.

James M. Wilson

Professor, Gene Therapy Program
University of Pennsylvania

James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago.

 

Jenny Tooth

CEO
UK Business Angels Association

Jenny is CEO of the UK Business Angels Association, the trade body for angel and early-stage investing, representing over 18,000 investors around the UK. Jenny has over 20 years’ experience of facilitating SMEs’ access to investment, both in the UK and internationally. She ran her own consultancy on access to finance for SMEs, including spending nine years based in Brussels, working closely with the EC. In 2009, Jenny co-founded Angel Capital Group which incorporates London Business Angels, one of the most established and active angel networks in the UK.

Jenny Tooth

CEO
UK Business Angels Association

Jenny is CEO of the UK Business Angels Association, the trade body for angel and early-stage investing, representing over 18,000 investors around the UK. Jenny has over 20 years’ experience of facilitating SMEs’ access to investment, both in the UK and internationally. She ran her own consultancy on access to finance for SMEs, including spending nine years based in Brussels, working closely with the EC. In 2009, Jenny co-founded Angel Capital Group which incorporates London Business Angels, one of the most established and active angel networks in the UK.

 

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

Joachim Hasenmaier

Member of the Board of Managing Directors
BOEHRINGER INGELHEIM

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

 

Karin Hoelzer

Senior Officer, Health Programs
The Pew Charitable Trusts

Karin Hoelzer is a senior officer in health programs supporting Pew’s safe food and antibiotic resistance projects.  Hoelzer, a veterinarian by training, focuses on research and policies related to foodborne pathogens, the use of antibiotics in animals, and other public health risks related to the food supply.  

Karin Hoelzer

Senior Officer, Health Programs
The Pew Charitable Trusts

Karin Hoelzer is a senior officer in health programs supporting Pew’s safe food and antibiotic resistance projects.  Hoelzer, a veterinarian by training, focuses on research and policies related to foodborne pathogens, the use of antibiotics in animals, and other public health risks related to the food supply.  

 

Kathrin Ladetzki-Baehs

Managing Director
Adivo

Dr. Kathrin Ladetzki-Baehs joined MorphoSys > 10 years ago as a scientist. Following several years of intense laboratory work in antibody generation as a project team leader, she became an alliance manger in 2012.

Today, Kathrin (Director at MorphoSys) coordinates multiple therapeutic antibody projects in close collaboration with international external partners at MorphoSys.

Kathrin Ladetzki-Baehs

Managing Director
Adivo

Dr. Kathrin Ladetzki-Baehs joined MorphoSys > 10 years ago as a scientist. Following several years of intense laboratory work in antibody generation as a project team leader, she became an alliance manger in 2012.

Today, Kathrin (Director at MorphoSys) coordinates multiple therapeutic antibody projects in close collaboration with international external partners at MorphoSys.

 

Kevin S. Wilson

Chief Executive Officer and President
Heska Corporation

Kevin S. Wilson has been Chief Executive Officer and President of Heska Corporation (HSKA: NASDQ) since March 31, 2014. He previously served as President and Chief Operating Officer since February 2013. Heska is based in Loveland, Colorado, has approximately 350 employees primarily throughout North America, and is dedicated to veterinary healthcare through its companion pet and equine diagnostics (blood and imaging) business and its vaccines, pharmaceuticals, and biologics segment. Since 1992, Mr.

Kevin S. Wilson

Chief Executive Officer and President
Heska Corporation

Kevin S. Wilson has been Chief Executive Officer and President of Heska Corporation (HSKA: NASDQ) since March 31, 2014. He previously served as President and Chief Operating Officer since February 2013. Heska is based in Loveland, Colorado, has approximately 350 employees primarily throughout North America, and is dedicated to veterinary healthcare through its companion pet and equine diagnostics (blood and imaging) business and its vaccines, pharmaceuticals, and biologics segment. Since 1992, Mr.

 

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

 

Marie-Paul Lachaud

Head of Program Management, Europe
Aratana Therapeutics, Inc

Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

Marie-Paul Lachaud

Head of Program Management, Europe
Aratana Therapeutics, Inc

Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.

Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development. 

 

Matt Dobbs

Managing Director, Ruminant and Insight
Origin

As Managing Director of Ruminant and Insight, Matt’s primary focus is on developing and improving the group’s people, services and products through providing a range of support services including training, research and consultancy. Matt has been published in several publications in the veterinary field, and has spoken at numerous conferences in the UK, USA, Europe and Australia.

Matt Dobbs

Managing Director, Ruminant and Insight
Origin

As Managing Director of Ruminant and Insight, Matt’s primary focus is on developing and improving the group’s people, services and products through providing a range of support services including training, research and consultancy. Matt has been published in several publications in the veterinary field, and has spoken at numerous conferences in the UK, USA, Europe and Australia.

 

Peter McCarthy

President, Global Animal Health Group
Henry Schein

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

Peter McCarthy

President, Global Animal Health Group
Henry Schein

Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.

Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.

 

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim
 

Sam Al-Murrani

CEO
Babylon BioConsulting LLC

Babylon BioConsulting LLC is a human and animal health-based consultancy firm specializing in pre-revenue and early stage valuations of Animal Health and Biotech companies and providing clients with investor outreach, due diligence, business development and intangible asset management and valuation services. Dr. Sam Al-Murrani is also Managing Director for Bimini LLC, a privately owned manufacturer of pet dose-form health supplements and health treats.

Sam Al-Murrani

CEO
Babylon BioConsulting LLC

Babylon BioConsulting LLC is a human and animal health-based consultancy firm specializing in pre-revenue and early stage valuations of Animal Health and Biotech companies and providing clients with investor outreach, due diligence, business development and intangible asset management and valuation services. Dr. Sam Al-Murrani is also Managing Director for Bimini LLC, a privately owned manufacturer of pet dose-form health supplements and health treats.

 

Sébastien Huron

Member of the Executive Board, Head of Global Business Operations
Virbac Santé Animale

Sébastien Huron, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division.

Sébastien Huron

Member of the Executive Board, Head of Global Business Operations
Virbac Santé Animale

Sébastien Huron, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division.

 

Simon Doherty

Junior Vice President
British Veterinary Association

Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.

 

Simon Doherty

Junior Vice President
British Veterinary Association

Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.

 

 

Simon Innes

Chief Executive
CVS Group

Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.

Simon Innes

Chief Executive
CVS Group

Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.

 

Sorina Casian Botez

Associate Director, Principal Investments
Eight Roads

As part of the Principal Investments team, Sorina drives the strategy for Eight Roads’ real estate portfolio and works with the management teams of healthcare portfolio investments and associated food and agriculture venture fund, Anterra Capital.

Sorina Casian Botez

Associate Director, Principal Investments
Eight Roads

As part of the Principal Investments team, Sorina drives the strategy for Eight Roads’ real estate portfolio and works with the management teams of healthcare portfolio investments and associated food and agriculture venture fund, Anterra Capital.

 

Tanja Hoel

CEO
The Seafood Innovation Cluster

Before being appointed General Manager of the Seafood Innovation Cluster in May 2015, Tanja was Managing Director of Fiskeriforum Vest (FFV) for 4 years. FFV was a regional network organization for the Seafood Industry in Western Norway, and a co-founder of the Seafood Innovation Cluster. Prior to that Tanja worked as a Project Manager at Norsk Sjømatsenter where she was managed a number of innovation and knowledge projects. Tanja was born and raised in Chicago but now lives with her family in Bergen.

Tanja Hoel

CEO
The Seafood Innovation Cluster

Before being appointed General Manager of the Seafood Innovation Cluster in May 2015, Tanja was Managing Director of Fiskeriforum Vest (FFV) for 4 years. FFV was a regional network organization for the Seafood Industry in Western Norway, and a co-founder of the Seafood Innovation Cluster. Prior to that Tanja worked as a Project Manager at Norsk Sjømatsenter where she was managed a number of innovation and knowledge projects. Tanja was born and raised in Chicago but now lives with her family in Bergen.

 

Viggo Halseth

Chief Innovation Officer
Nutreco

Viggo joined Nutreco in 1984. He has a longstanding career in Nutreco and had various positions in marketing, general and business unit management within Skretting ARC and Skretting. Viggo studied Animal Hubandry at Agriculture University and Marketing and Strategy Development at Norwegian Business School.

Viggo Halseth

Chief Innovation Officer
Nutreco

Viggo joined Nutreco in 1984. He has a longstanding career in Nutreco and had various positions in marketing, general and business unit management within Skretting ARC and Skretting. Viggo studied Animal Hubandry at Agriculture University and Marketing and Strategy Development at Norwegian Business School.

Innovation Showcase

The Innovation Showcase is a chance for emerging and pre-revenue organisations to pitch their company in front of a room of investors.

Applications are now closed for the London 2018 Showcase.

Our Selection Committee now have the exciting job of selecting twelve companies from over thirty applications to present on-site to the audience. These presentations will showcase the innovation and opportunity that the emerging companies bring to their various markets.

Results will be announced in early January - watch this space!

NEW FOR 2018!

Kisaco Research have teamed up with Stonehaven Consulting AG to offer a FREE HALF-DAY OF CONSULTATION to each of the twelve emerging companies that will be selected to present.

Stonehaven Consulting AG are a premier consulting company that specialises in assisting ambitious clients wanting to commercialise new technologies or leverage growth opportunities. They will give one of their partners’ services to each presenting company, for a full half day ahead of the conference.

This is an excellent opportunity, with the chance for each presenting company to focus on an area of their choice; for example:

  • Advice on how to select the right Business/Financing Partners
  • Building and telling a story which appeals to investors
  • Advice on how to improve or optimize your Animal Health Investment Europe conference presentation
  • Strategic considerations pertaining your business
  • and more…

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Who Will Be There

Headline Partner

Associate Partners

Consulting Partner

Event Partners

Media Partners

Become a Sponsor or Exhibitor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].